Comprehensive Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer in the Era of Precision Medicine: Construction and Optimization of A Learning-Oriented Multidisciplinary Team System
10.3971/j.issn.1000-8578.2026.26.0002
- VernacularTitle:精准医学时代EGFR突变阳性非小细胞肺癌的全程管理：学习型MDT体系的构建与优化
- Author:
Li LYU
1
;
Meixian LI
1
;
Jie LIN
1
Author Information
1. Department of Medical Oncology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China.
- Publication Type:SPECIALFEATURE
- Keywords:
Precision medicine;
EGFR mutation;
Non-small cell lung cancer;
Learning-oriented multidisciplinary team;
Comprehensive management;
Evidence-based decision-making
- From:
Cancer Research on Prevention and Treatment
2026;53(8):577-588
- CountryChina
- Language:Chinese
-
Abstract:
In the era of precision medicine, therapeutic strategies for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) have become increasingly advanced. However, conventional multidisciplinary team (MDT) models fail to address the demands of dynamic whole-course disease management. This review proposes an evolved learning-oriented MDT system for the standardized management of EGFR mutation-positive NSCLC. Grounded in evidence-based medicine, centered on expert decision-making, and supported by digital integration, this system enables the comprehensive evaluation of patients' individual characteristics, including performance status, psychosocial conditions, and economic affordability. This article elucidates the core management objectives and key PICO-style clinical questions for EGFR mutation-positive NSCLC across critical disease stages, including resectable early-stage disease, stage Ⅲ disease, metastatic/oligoprogressive disease, and tyrosine kinase inhibitor-resistant disease. Based on updated quantitative clinical evidence, we develop a structured framework for the learning-oriented MDT system, covering a multidimensional collaborative structure, standardized node-based workflows, a full-cycle information integration platform, quantitative evaluation indicators, and a closed-loop optimization mechanism. Notably, we propose a multicenter prospective randomized controlled trial design to validate the clinical efficacy of this system. This review analyzes the implementation limitations and potential social impacts of the system and proposes phased optimization and mitigation strategies. This work provides a theoretical framework and practical guidance for establishing a standardized, precise, and humanistic whole-course management model for EGFR mutation-positive NSCLC.
